We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) intends to launch five major vaccines over the next five years as part of an aggressive strategy to tap into markets it believes could grow to upwards of $18 billion by 2010.
Merck’s two clinical studies examining the safety of its yet-to-be-approved Cox-2 inhibitor Arcoxia are allowed to continue following a recent meeting of a Data Safety Monitoring Board (DSMB) responsible for overseeing the trials.
The FDA has requested a safety analysis of a new Novartis multiple sclerosis (MS) treatment, prompting the drugmaker to delay the Phase III clinical trials of FTY720 by three or four months until the fourth quarter, Novartis announced June 21.
Building relationships with patient advocacy groups can help pharmaceutical firms speed the drug-development process, including during the all-important clinical trial phases, experts told the Biotechnology Industry Organization (BIO) annual conference.
Merck’s two clinical studies examining the safety of its yet-to-be-approved Cox-2 inhibitor Arcoxia are allowed to continue following a recent meeting of a Data Safety Monitoring Board (DSMB) responsible for overseeing the trials.
Clinical investigators are increasingly turning to industry sponsors to help them cover “hidden” trial costs — such as prestudy services — that are starting to eat away at research institutions’ operating budgets.
A numbers model that has been around for over a decade but underused by medical researchers could help scientists conduct more organized and thorough clinical trials, according to a psychiatrist who recently published a book on the topic.
Recent criticism from the medical journal community, which accused drugmakers of withholding information from online public trial registries, is unfounded and unfair, according to a pair of large pharmaceutical firms that said they are doing everything in their power to improve transparency and accessibility.
The FDA’s accelerated approval process for drugs is “broken,” contends a top Democratic representative, who says many drug companies aren’t completing the postmarketing studies they pledged to conduct after gaining approval of their products.
Some pharmaceutical manufacturers are providing incomplete clinical trial data to online registries, according to International Committee of Medical Journal Editors (ICMJE), which says firms and other sponsors must provide useful and complete information for a clinical study to be eligible for publication.